Recent US drug recalls
Every drug recall the FDA has reported, most serious first.
Every drug recall the FDA has reported, most serious first.
The FDA publishes recalls weekly, so this runs to its latest update, not today. Class I is the most serious.
Particulate matter: particulate matter identified as cellulose, polystyrene, polyethylene teraphalate, stainless steel, or stopper material in the product solution.
Microbial Contamination of Sterile Products
Particulate matter: particulate matter identified as cellulose, polystyrene, polyethylene teraphalate, stainless steel, or stopper material in the product solution.
Superpotent Drug
Presence of Particulate Matter and Lack of Assurance of Sterility. Particulate matter identified as nylon, cellulosic, acrylic, polyethylene and glass and broken and leaking vials.
Presence of Particulate Matter: particulate matter identified as stainless steel particles in the solution.
Presence of Particulate Matter: particulate matter identified as iron oxide, inorganic material, cellulose cotton fiber or polystyrene
Microbial Contamination of Sterile Products - out of specifications results were obtained for bacterial endotoxin.
Presence of particulate matter: Particulates identified as fiberglass
Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles.
Presence of Particulate matter.
Presence of Particulate Matter: Product contaminated with particulate matter identified as glass and/or paraformaldehyde
Labeling: Label Mixup: MicroVault labeled as Morphine 2 mg/1 mL, contains a Prefilled Syringe of Dilaudid 0.5 mg/0.5 mL.
Marketed Without an Approved NDA/ANDA: Product contains undeclared drug ingredients dexamethasone and cyproheptadine.
Microbial Contamination of Sterile Products - out of specifications results were obtained for bacterial endotoxin.
Presence of Particulate Matter: comprising polyethylene and other plastic materials, stainless steel and glass.
Presence of Particulate Matter
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
Lack of Assurance of Sterility
Presence of particulate matter:American Regent, Inc. notified BluePoint Pharmaceuticals Laboratories regarding potential glass particle contamination (foreign glass fragment) identified in the product batch.
Lack of Processing Controls
Lack of Assurance of Sterility:complaints have been received related to potential leaks from small perforations in the print area on the primary bag in the affected lots.
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
Lack of Assurance of Sterility:complaints have been received related to potential leaks from small perforations in the print area on the primary bag in the affected lots.
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
Failed Stability Specifications: OOS stability results included viscosity and appearance results that did not align with the established specifications.
Failed Stability Specifications: OOS stability results included viscosity and appearance results that did not align with the established specifications.
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
Lack of Assurance of Sterility:complaints have been received related to potential leaks from small perforations in the print area on the primary bag in the affected lots.
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
Lack of Assurance of Sterility:complaints have been received related to potential leaks from small perforations in the print area on the primary bag in the affected lots.
Failed Impurities/Degradation Specifications
Lack of Processing Controls
Presence of Foreign Tablets/Capsules
Lack of Processing Controls
Lack of Processing Controls
Failed Stability Specifications: OOS stability results included viscosity and appearance results that did not align with the established specifications.
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
Lack of Assurance of Sterility:complaints have been received related to potential leaks from small perforations in the print area on the primary bag in the affected lots.
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit.
Lack of Processing Controls
CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit.
Lack of Processing Controls
Lack of Processing Controls
Lack of Processing Controls
CGMP Deviations
CGMP Deviations
Failed Dissolution Specifications.
CGMP Deviations
Failed Impurities/Degradation Specification; detection of polyethylene (PE)-related oligomers
CGMP Deviations
CGMP Deviations
CGMP Deviations
CGMP Deviations
Manufacturer is recalling batches due to co-mingled tablet.
CGMP Deviations
Failed Impurities/Degradation Specification
CGMP Deviations
Subpotent Drug
CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory
CGMP Deviations
CGMP Deviations
CGMP Deviations
CGMP Deviations
CGMP Deviations
Lack of Assurance of Sterility
CGMP Deviations
Presence of Foreign Tablets/Capsules
Lack of Assurance of Sterility
Labeling: Not Elsewhere Classified
CGMP Deviations
CGMP Deviations
CGMP Deviations
CGMP Deviations
CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory
CGMP Deviations
CGMP Deviations.
CGMP Deviations.
CGMP Deviations.
CGMP Deviations.
CGMP Deviations.
CGMP Deviations.
Failed dissolution specifications
CGMP Deviations.
Failed Tablet/Capsule Specifications: Failed tablet specifications for weight uniformity.
Lack of Assurance of Sterility
CGMP Deviations.
CGMP Deviations.
CGMP Deviations.
Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.
CGMP Deviations.
Out of specification due to dissolution.
CGMP Deviations.
CGMP Deviations
CGMP Deviations
Lack of sterility assurance.
Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.
CGMP Deviations
CGMP Deviations.
CGMP Deviations.
Lack of process control
Presence of Foreign Tablets/Capsules
Presence of Foreign Tablets/Capsules
Failed Impurities/Degradation Specifications.
Lack of assurance of sterility.
Lack of Assurance of Sterility
Lack of Assurance of Sterility: Related to processing equipment used in compounded product.
Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.
Lack of Assurance of Sterility: Related to processing equipment used in compounded product.
Lack of Assurance of Sterility: Related to processing equipment used in compounded product.
Lack of Assurance of Sterility: Related to processing equipment used in compounded product.
Lack of Assurance of Sterility
Failed Impurities/Degradation Specifications
Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.
Presence of particulate matter.
Lack of Assurance of Sterility
Lack of Assurance of Sterility: Related to processing equipment used in compounded product.
Lack of Assurance of Sterility
Failed Content Uniformity Specifications
Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.
Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.
Lack of Assurance of Sterility
Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.
Lack of Assurance of Sterility
Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.
Failed stability specifications
Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.
Lack of Assurance of Sterility
Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.
Lack of Assurance of Sterility
Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.
Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.
Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Microbial contamination of topical product.
Defective Container; packets were found to be either empty or partially full.
Lack of Assurance of Sterility
Temperature Abuse: Product sat in a non-temperature-controlled FedEx trailer at ambient outdoor conditions for 25.5 hours.
Failed dissolution specifications.
Microbial contamination of topical product.
Crystallization
Failed Dissolution Specifications: below specification
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Defective Delivery System: Possibility of no medication in the prefilled pen.
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Lack of Assurance of Sterility
cGMP Deviations
Failed Stability Specifications
Failed Stability Specifications
Failed Stability Specifications
Failed Stability Specifications
Failed Stability Specifications
Failed Stability Specifications
Failed Content Uniformity Specifications. Out of Specification for Assay during analysis at the 24- month long term stability station, at (25¿C,60%RH).
Failed Dissolution Specifications
Lack of Assurance of Sterility
Labeling: Not Elsewhere Classified: Complaint received on 08/31/2026 regarding the discrepancy of the IV bag expiry (07/31/2026 and 11/30/2026) and the product expiry (12/09/2026).
CGMP Deviations
CGMP Deviations
CGMP Deviations
CGMP Deviations
Presence of Foreign Tablets/Capsules
Subpotent Product: Firm Testing indicated the affected product may not reliably provide the SPF 50 protection stated on the label.
Subpotent Product: Firm Testing indicated the affected product may not reliably provide the SPF 50 protection stated on the label.
CGMP Deviations
CGMP Deviations: Potential contamination of raw material
CGMP Deviations
CGMP Deviations
CGMP Deviations
Subpotent Product: Firm Testing indicated the affected product may not reliably provide the SPF 50 protection stated on the label.
CGMP Deviations
Subpotent Product: Firm Testing indicated the affected product may not reliably provide the SPF 50 protection stated on the label.
CGMP Deviations
CGMP Deviations: Potential contamination of raw material
CGMP Deviations
CGMP Deviations
CGMP Deviations
CGMP Deviations
Cross Contamination with Other Products
Failed Dissolution Specifications; product failed to meet 18-month stability testing acceptance criteria
CGMP Deviations
CGMP Deviations
CGMP Deviations
Failed Dissolution Specifications
Failed Dissolution Specifications. Notification from the manufacturer that lot is being recalled due to failed dissolution
Subpotent Drug
Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclohexylurea (DCU).
Subpotent Drug
Subpotent Drug
Subpotent Drug
Subpotent Drug
Failed content uniformity specifications.
Subpotent Drug
Subpotent Drug
Presence of particulate matter: glass and stopper piece
Subpotent Drug
CGMP Deviations; FDA inspection of the contract manufacturer noted out of limit results for microbiological testing
Subpotent Drug
Subpotent Drug
Subpotent Drug
Subpotent Drug
Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria
Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
CGMP deviations: tablets with black specks.
Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
Discolored solution. The firm has received market complaints reporting green to dark green discoloration in certain vials
Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
Lack of Assurance of Sterility
Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
Failed Dissolution Specifications
Discolored solution. The firm has received market complaints reporting green to dark green discoloration in certain vials
Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
CGMP Deviations; black spots found on tablets from burnt excipient during manufacturing
Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
CGMP Deviations:Noted during FDA inspection
Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material
Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material
Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material
Presence of Foreign Substance: presence of particles and white flakes in the reconstituted bottles.
Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material
Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material
Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material
Lack of assurance of sterility. The recall is due to potential contamination
Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material
Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material
Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material
CGMP Deviations:Noted during FDA inspection
CGMP Deviations:Noted during FDA inspection
Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material
Failed Dissolution Specifications
Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material
CGMP Deviations:Noted during FDA inspection
CGMP Deviations:Noted during FDA inspection
Labeling: Label Lacks Warning or Rx Legend
Labeling: Label Lacks Warning or Rx Legend
Incorrect label placed on product: Outer carton label correctly identifies drug product in bottle as ValuHealth Extra Strength Pain Relief Acetaminophen 500 mg,but inner label on bottle says ValuHealth Extra Strength Pain Relief PM
Superpotent Drug: potential for the Telmisartan content in these lots to exceed specifications
Failed Impurities/Degradation Specifications
Failed Impurities/Degradation Specifications
Failed Impurities/Degradation Specifications
Failed Impurities/Degradation Specifications:Organic and unspecified impurities above specification.
Subpotent Drug
Failed impurities/degradation specifications: (OOS) for Organic Impurities by HPLC (Impurity-A) during testing at the 18 months long term stability. Result: 1.1 percent. Spec: 1.0 percent.
Failed dissolution specifications.
Labeling: Label Mix-up
Presence of Foreign Tablets/Capsules
Failed Stability Specifications: Out of specification stability result for the protein concentration profile.
Microbial Contamination of Sterile Products: Out of specifications results were obtained for bacterial endotoxin.
Microbial Contamination of Sterile Products - out of specifications results were obtained for bacterial endotoxin.